Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 2/20 | 0.58 |
| ▸ | MRGPRX4 | Q96LA9 | 6/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | PREP | P48147 | 1/20 | 0.48 |
| ▸ | FAP | Q12884 | 1/20 | 0.48 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.48 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL663986 | 0.94 | MAP4K4 (0.54) | KMOMRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10148399 | 0.88 | KDM5A (0.54) | KMOMRGPRX4DPP4PREPFAP | |
| SCHEMBL1013024 | 0.88 | KMO (0.52) | KMOHPGDPDE4APDE4BPDE4C | |
| SCHEMBL28034346 | 0.86 | PDE4B (0.53) | NR1H4TSHRMAP4K4POLBPDE4A | |
| SCHEMBL3170758 | 0.85 | KMO (0.50) | KMOPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1391337 | 0.84 | KMO (0.49) | KMOMRGPRX4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31325672 | 0.82 | NR1H4 (0.48) | KMONR1H4MAP4K4KDM2BKDM4C | |
| SCHEMBL15968784 | 0.82 | LMNA (0.55) | MRGPRX4RAB9ANR1H4MAP4K4LMNA | |
| SCHEMBL15968144 | 0.82 | DPP4 (0.48) | KMODPP4NR1H4MAP4K4KDM2B | |
| SCHEMBL10148378 | 0.82 | NR1H4 (0.48) | MRGPRX4NR1H4MAP4K4KDM2BKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9133129-B2 | Bicyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-09-15 | — | — | US | disclosed |
| EP-2772485-A1 | BICYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-20140243310-A1 | BICYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-28 | — | — | US | disclosed |
| US-8329730-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2012-12-11 | — | — | US | disclosed |
| EP-2271643-B1 | OXADIAZOLES AS S1P1 RECEPTOR AGONISTS | GLAXO GROUP LTD (GB) | 2012-08-15 | — | — | EP | disclosed |
| US-20110039889-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-02-17 | — | — | US | disclosed |
| EP-2271643-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-01-12 | — | — | EP | disclosed |
| WO-2009133136-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039889-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | KMO 1640/4885MRGPRX4 1004/4885NPC1 70/4885 |
| US-20140243310-A1 | BICYCLIC COMPOUND | BICRA, NR3C2, CYP11B2 | KMO 2615/4885MRGPRX4 1167/4885NPC1 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.